Multiple Sclerosis - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 256

Multiple Sclerosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, Global Markets Direct’s, 'Multiple Sclerosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Multiple Sclerosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Multiple Sclerosis. Multiple Sclerosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
- A review of the Multiple Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Multiple Sclerosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Multiple Sclerosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Multiple Sclerosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 6
List of Figures 10
Introduction 11
REPORT COVERAGE 11
Multiple Sclerosis Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Multiple Sclerosis 13
Multiple Sclerosis Therapeutics under Development by Companies 15
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes 27
Late Stage Products 31
Comparative Analysis 31
Mid Clinical Stage Products 32
Comparative Analysis 32
Early Clinical Stage Products 33
Comparative Analysis 33
Discovery and Pre-Clinical Stage Products 34
Comparative Analysis 34
Multiple Sclerosis Therapeutics – Products under Development by Companies 35
Multiple Sclerosis Therapeutics – Products under Investigation by Universities/Institutes 40
Companies Involved in Multiple Sclerosis Therapeutics Development 42
Alcon, Inc. 42
Genzyme Corporation 43
Baxter International Inc. 44
F. Hoffmann-La Roche Ltd. 45
Abbott Laboratories 46
Biogen Idec Inc. 47
Amgen Inc. 48
Eli Lilly and Company 49
Athersys, Inc. 50
GlaxoSmithKline plc 51
MedImmune LLC 52
Daiichi Sankyo Company, Ltd 53
Cytokine PharmaSciences, Inc. 54
XenoPort, Inc. 55
Apitope International NV 56
Novartis AG 57
Acorda Therapeutics, Inc. 58
Actelion Ltd 59
Astellas Pharma Inc. 60
Dong-A Pharmaceutical Co., Ltd. 61
Elan Corporation, plc 62
Glenmark Pharmaceuticals Ltd. 63
Mitsubishi Tanabe Pharma Corporation 64
Ono Pharmaceutical Co., Ltd. 65
Rigel Pharmaceuticals, Inc. 66
Teva Pharmaceutical Industries Limited 67
Vertex Pharmaceuticals Incorporated 68
Zydus Cadila Healthcare Limited 69
Genmab A/S 70
novosom AG 71
Paratek Pharmaceuticals, Inc. 72
Celgene Corporation 73
BrainStorm Cell Therapeutics Inc. 74
Merck KGaA 75
4SC AG 76
Addex Pharmaceuticals 77
Evotec Aktiengesellschaft 78
Genesis Research and Development Corporation Ltd. 79
Hemispherx Biopharma, Inc. 80
Hollis-Eden Pharmaceuticals, Inc. 81
Momenta Pharmaceuticals, Inc. 82
Antisense Therapeutics Limited 83
Idera Pharmaceuticals, Inc. 84
Karo Bio 85
Almirall, S.A. 86
Lpath, Inc. 87
Bionomics Limited 88
PROLOR Biotech, Inc. 89
MultiCell Technologies, Inc. 90
Nutra Pharma Corporation 91
Opexa Therapeutics, Inc. 92
Compugen Ltd. 93
Critical Outcome Technologies Inc. 94
Accentia Biopharmaceuticals, Inc. 95
Arena Pharmaceuticals, Inc. 96
Zenotech Laboratories Limited 97
RegeneRx Biopharmaceuticals, Inc. 98
Tolerx, Inc. 99
ProMetic Life Sciences Inc. 100
MorphoSys AG 101
Lipoxen PLC 102
Hanall Pharmaceutical Co., Ltd. 103
Cytos Biotechnology AG 104
Pluristem Therapeutics Inc. 105
Sareum Holdings plc 106
Santhera Pharmaceuticals Holding AG 107
Transgene Biotek Ltd 108
Shenzhen Beike Biotechnology Co., Ltd. 109
Stem Cell Therapeutics Corp. 110
Morphotek, Inc. 111
Digna Biotech, S.L. 112
Avanti Therapeutics 113
Axxam SpA 114
Bayhill Therapeutics, Inc. 115
Phenex Pharmaceuticals AG 116
Hutchison MediPharma Limited 117
Trophos SA 118
Artielle ImmunoTherapeutics, Inc. 119
Affectis Pharmaceuticals AG 120
ProtAffin Biotechnologie AG 121
Allozyne, Inc. 122
Coronado Biosciences, Inc. 123
Q Therapeutics, Inc. 124
Catabasis Pharmaceuticals, Inc. 125
Vaccinex, Inc. 126
Innate Therapeutics Limited 127
Kineta, Inc. 128
Deciphera Pharmaceuticals, LLC 129
MSM Protein Technologies, Inc. 130
Vascular Biogenics Ltd. 131
Txcell SA 132
Theraclone Sciences, Inc. 133
Siena Biotech S.p.A. 134
Omeros Corporation 135
Bolder Biotechnology, Inc. 136
Aegis Therapeutics, LLC 137
Xencor, Inc. 138
Adeona Pharmaceuticals, Inc. 139
Trillium Therapeutics Inc. 140
ChemoCentryx, Inc. 141
Cellceutix Corporation 142
Biovista Inc. 143
CBio Limited 144
SanBio, Inc. 145
AB Science 146
Provid Pharmaceuticals, Inc. 147
Epiphany Biosciences, Inc. 148
Biokine Therapeutics Ltd. 149
KYORIN Pharmaceutical Co., Ltd. 150
OncoImmune, Inc. 151
to-BBB technologies BV 152
Daval International Ltd. 153
Hy BioPharma Inc. 154
Medistem, Inc. 155
PharmaEssentia Corporation 156
Nuon Therapeutics, Inc. 157
KAHR medical Ltd. 158
M's Science Corporation 159
Centocor Ortho Biotech, Inc. 160
Pharnext SAS 161
Amplimmune, Inc. 162
Lycera Corp. 163
Neuraltus Pharmaceuticals, Inc. 164
Vakzine Projekt Management GmbH 165
Receptos, Inc. 166
Biopartners Holdings AG 167
Pfenex Inc. 168
Cellmid Ltd 169
Synthon BV 170
Cognosci, Inc. 171
Immune Technologies and Medicine 172
Celtaxsys, Inc. 173
Multiple Sclerosis – Therapeutics Assessment 174
Assessment by Monotherapy Products 174
Assessment by Combination Products 175
Assessment by Route of Administration 176
Assessment by Molecule Type 178
Drug Profiles 180
teriflunomide - Drug Profile 180
teriflunomide - Drug Profile 182
laquinimod sodium - Drug Profile 184
laquinimod sodium - Drug Profile 186
ocrelizumab - Drug Profile 188
Campath - Drug Profile 190
daclizumab - Drug Profile 192
PEGylated Interferon Beta-1A - Drug Profile 194
recombinant IFN Beta-1b - Drug Profile 195
minocycline - Drug Profile 196
dimethyl fumarate - Drug Profile 198
Ocrelizumab + Methylprednisolone - Drug Profile 200
methylprednisolone - Drug Profile 202
interferon beta-1a - Drug Profile 203
methylprednisolone - Drug Profile 204
Memantine - Drug Profile 205
aspirin - Drug Profile 206
Lutenyl + Dermestril Septem - Drug Profile 207
interferon beta-1b biosimilar - Drug Profile 208
alemtuzumab - Drug Profile 209
Hematopoietic Stem Cell Therapy - Drug Profile 210
Glatiramer Acetate - Drug Profile 212
M356 - Drug Profile 213
Multiple Sclerosis Therapeutics – Drug Profile Updates 214
Multiple Sclerosis Therapeutics – Discontinued Products 234
Multiple Sclerosis Therapeutics - Dormant Products 237
Multiple Sclerosis – Product Development Milestones 246
Featured News & Press Releases 246
Appendix 253
Methodology 253
Coverage 253
Secondary Research 253
Primary Research 253
Expert Panel Validation 253
Contact Us 254
Disclaimer 254

List of Tables
Number of Products Under Development for Multiple Sclerosis, H2 2012 15
Products under Development for Multiple Sclerosis – Comparative Analysis, H2 2012 16
Number of Products under Development by Companies, H2 2012 18
Number of Products under Development by Companies, H2 2012 (Contd..1) 19
Number of Products under Development by Companies, H2 2012 (Contd..2) 20
Number of Products under Development by Companies, H2 2012 (Contd..3) 21
Number of Products under Development by Companies, H2 2012 (Contd..4) 22
Number of Products under Development by Companies, H2 2012 (Contd..5) 23
Number of Products under Development by Companies, H2 2012 (Contd..6) 24
Number of Products under Development by Companies, H2 2012 (Contd..7) 25
Number of Products under Development by Companies, H2 2012 (Contd..8) 26
Number of Products under Development by Companies, H2 2012 (Contd..9) 27
Number of Products under Development by Companies, H2 2012 (Contd..10) 28
Number of Products under Investigation by Universities/Institutes, H2 2012 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 32
Comparative Analysis by Late Stage Development, H2 2012 33
Comparative Analysis by Mid Clinical Stage Development, H2 2012 34
Comparative Analysis by Early Clinical Stage Development, H2 2012 35
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 36
Products under Development by Companies, H2 2012 37
Products under Investigation by Universities/Institutes, H2 2012 42
Alcon, Inc., H2 2012 44
Genzyme Corporation, H2 2012 45
Baxter International Inc., H2 2012 46
F. Hoffmann-La Roche Ltd., H2 2012 47
Abbott Laboratories, H2 2012 48
Biogen Idec Inc., H2 2012 49
Amgen Inc., H2 2012 50
Eli Lilly and Company, H2 2012 51
Athersys, Inc., H2 2012 52
GlaxoSmithKline plc, H2 2012 53
MedImmune LLC, H2 2012 54
Daiichi Sankyo Company, Ltd, H2 2012 55
Cytokine PharmaSciences, Inc., H2 2012 56
XenoPort, Inc., H2 2012 57
Apitope International NV, H2 2012 58
Novartis AG, H2 2012 59
Acorda Therapeutics, Inc., H2 2012 60
Actelion Ltd, H2 2012 61
Astellas Pharma Inc., H2 2012 62
Dong-A Pharmaceutical Co., Ltd., H2 2012 63
Elan Corporation, plc, H2 2012 64
Glenmark Pharmaceuticals Ltd., H2 2012 65
Mitsubishi Tanabe Pharma Corporation, H2 2012 66
Ono Pharmaceutical Co., Ltd., H2 2012 67
Rigel Pharmaceuticals, Inc., H2 2012 68
Teva Pharmaceutical Industries Limited, H2 2012 69
Vertex Pharmaceuticals Incorporated, H2 2012 70
Zydus Cadila Healthcare Limited, H2 2012 71
Genmab A/S, H2 2012 72
novosom AG, H2 2012 73
Paratek Pharmaceuticals, Inc., H2 2012 74
Celgene Corporation, H2 2012 75
BrainStorm Cell Therapeutics Inc., H2 2012 76
Merck KGaA, H2 2012 77
4SC AG, H2 2012 78
Addex Pharmaceuticals, H2 2012 79
Evotec Aktiengesellschaft, H2 2012 80
Genesis Research and Development Corporation Ltd., H2 2012 81
Hemispherx Biopharma, Inc., H2 2012 82
Hollis-Eden Pharmaceuticals, Inc., H2 2012 83
Momenta Pharmaceuticals, Inc., H2 2012 84
Antisense Therapeutics Limited, H2 2012 85
Idera Pharmaceuticals, Inc., H2 2012 86
Karo Bio, H2 2012 87
Almirall, S.A., H2 2012 88
Lpath, Inc., H2 2012 89
Bionomics Limited, H2 2012 90
PROLOR Biotech, Inc., H2 2012 91
MultiCell Technologies, Inc., H2 2012 92
Nutra Pharma Corporation, H2 2012 93
Opexa Therapeutics, Inc., H2 2012 94
Compugen Ltd., H2 2012 95
Critical Outcome Technologies Inc., H2 2012 96
Accentia Biopharmaceuticals, Inc., H2 2012 97
Arena Pharmaceuticals, Inc., H2 2012 98
Zenotech Laboratories Limited, H2 2012 99
RegeneRx Biopharmaceuticals, Inc., H2 2012 100
Tolerx, Inc., H2 2012 101
ProMetic Life Sciences Inc., H2 2012 102
MorphoSys AG, H2 2012 103
Lipoxen PLC, H2 2012 104
Hanall Pharmaceutical Co., Ltd., H2 2012 105
Cytos Biotechnology AG, H2 2012 106
Pluristem Therapeutics Inc., H2 2012 107
Sareum Holdings plc, H2 2012 108
Santhera Pharmaceuticals Holding AG, H2 2012 109
Transgene Biotek Ltd, H2 2012 110
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 111
Stem Cell Therapeutics Corp., H2 2012 112
Morphotek, Inc., H2 2012 113
Digna Biotech, S.L., H2 2012 114
Avanti Therapeutics, H2 2012 115
Axxam SpA, H2 2012 116
Bayhill Therapeutics, Inc., H2 2012 117
Phenex Pharmaceuticals AG, H2 2012 118
Hutchison MediPharma Limited, H2 2012 119
Trophos SA, H2 2012 120
Artielle ImmunoTherapeutics, Inc., H2 2012 121
Affectis Pharmaceuticals AG, H2 2012 122
ProtAffin Biotechnologie AG, H2 2012 123
Allozyne, Inc., H2 2012 124
Coronado Biosciences, Inc., H2 2012 125
Q Therapeutics, Inc., H2 2012 126
Catabasis Pharmaceuticals, Inc., H2 2012 127
Vaccinex, Inc., H2 2012 128
Innate Therapeutics Limited, H2 2012 129
Kineta, Inc., H2 2012 130
Deciphera Pharmaceuticals, LLC, H2 2012 131
MSM Protein Technologies, Inc., H2 2012 132
Vascular Biogenics Ltd., H2 2012 133
Txcell SA, H2 2012 134
Theraclone Sciences, Inc., H2 2012 135
Siena Biotech S.p.A., H2 2012 136
Omeros Corporation, H2 2012 137
Bolder Biotechnology, Inc., H2 2012 138
Aegis Therapeutics, LLC, H2 2012 139
Xencor, Inc., H2 2012 140
Adeona Pharmaceuticals, Inc., H2 2012 141
Trillium Therapeutics Inc., H2 2012 142
ChemoCentryx, Inc., H2 2012 143
Cellceutix Corporation, H2 2012 144
Biovista Inc., H2 2012 145
CBio Limited, H2 2012 146
SanBio, Inc., H2 2012 147
AB Science, H2 2012 148
Provid Pharmaceuticals, Inc., H2 2012 149
Epiphany Biosciences, Inc., H2 2012 150
Biokine Therapeutics Ltd., H2 2012 151
KYORIN Pharmaceutical Co., Ltd., H2 2012 152
OncoImmune, Inc., H2 2012 153
to-BBB technologies BV, H2 2012 154
Daval International Ltd., H2 2012 155
Hy BioPharma Inc., H2 2012 156
Medistem, Inc., H2 2012 157
PharmaEssentia Corporation, H2 2012 158
Nuon Therapeutics, Inc., H2 2012 159
KAHR medical Ltd., H2 2012 160
M's Science Corporation, H2 2012 161
Centocor Ortho Biotech, Inc., H2 2012 162
Pharnext SAS, H2 2012 163
Amplimmune, Inc., H2 2012 164
Lycera Corp., H2 2012 165
Neuraltus Pharmaceuticals, Inc., H2 2012 166
Vakzine Projekt Management GmbH, H2 2012 167
Receptos, Inc., H2 2012 168
Biopartners Holdings AG, H2 2012 169
Pfenex Inc., H2 2012 170
Cellmid Ltd, H2 2012 171
Synthon BV, H2 2012 172
Cognosci, Inc., H2 2012 173
Immune Technologies and Medicine, H2 2012 174
Celtaxsys, Inc., H2 2012 175
Assessment by Monotherapy Products, H2 2012 176
Assessment by Combination Products, H2 2012 177
Assessment by Stage and Route of Administration, H2 2012 179
Assessment by Stage and Molecule Type, H2 2012 181
Multiple Sclerosis Therapeutics – Drug Profile Updates 216
Multiple Sclerosis Therapeutics – Discontinued Products 236
Multiple Sclerosis Therapeutics – Discontinued Products (Contd..1) 237
Multiple Sclerosis Therapeutics – Discontinued Products (Contd..2) 238
Multiple Sclerosis Therapeutics – Dormant Products 239
Multiple Sclerosis Therapeutics – Dormant Products (Contd..1) 240
Multiple Sclerosis Therapeutics – Dormant Products (Contd..2) 241
Multiple Sclerosis Therapeutics – Dormant Products (Contd..3) 242
Multiple Sclerosis Therapeutics – Dormant Products (Contd..4) 243
Multiple Sclerosis Therapeutics – Dormant Products (Contd..5) 244
Multiple Sclerosis Therapeutics – Dormant Products (Contd..6) 245
Multiple Sclerosis Therapeutics – Dormant Products (Contd..7) 246
Multiple Sclerosis Therapeutics – Dormant Products (Contd..8) 247

List of Figures
Number of Products under Development for Multiple Sclerosis, H2 2012 15
Products under Development for Multiple Sclerosis – Comparative Analysis, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 29
Late Stage Products, H2 2012 33
Mid Clinical Stage Products, H2 2012 34
Early Clinical Stage Products, H2 2012 35
Discovery and Pre-Clinical Stage Products, H2 2012 36
Assessment by Monotherapy Products, H2 2012 176
Assessment by Combination Products, H2 2012 177
Assessment by Route of Administration, H2 2012 178
Assessment by Stage and Route of Administration, H2 2012 179
Assessment by Molecule Type, H2 2012 180
Assessment by Stage and Molecule Type, H2 2012 181

Customers who bought this item also bought

• Psoriasis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012
• Hepatitis - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Alzheimer's Disease - Pipeline Review, H2 2012
• Anemia - Pipeline Review, H2 2012